Effects of lipid-lowering treatment on platelet reactivity and plateletleukocyte aggregation in diabetic patients without and with chronic kidney disease: A randomized trial

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3540-3546

  Almquist, Tora ^a,b   Jacobson, Stefan H ^b   Lins, Per Eric ^b   Farndale, Richard W ^c   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

chronic kidney disease; diabetes mellitus; inflammation; platelet function; plateletleukocyte aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; ELASTASE; ENALAPRIL; EZETIMIBE; HEMOGLOBIN A1C; SIMVASTATIN; TROMBYL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART MUSCLE REVASCULARIZATION; HUMAN; LEUKOCYTE; LEUKOCYTE AGGREGATION; MALE; METABOLIC REGULATION; NEUTROPHIL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD PLATELETS; CROSS-OVER STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; LIPIDS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PROGNOSIS; RISK FACTORS; SIMVASTATIN; YOUNG ADULT;

EID: 84865762062     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs183     Document Type: Article

References (42)

1. Executive summary: Standards of medical care in diabetes-2010. Diabetes Care 2010; 33: 4-10.
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
3. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population,1998 to1999. J Am Soc Nephrol 2005; 16: 489-495.
4. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J AM Coll Cardiol 2009; 54: 2129-2138.
5. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-1652.
6. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253.
7. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
8. Li N, Hu H, Lindqvist M et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-2708.
9. Sarma J, Laan CA, Alam S et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
10. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
11. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105: 43-54.
12. Hu H, Li N, Yngen M et al. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 2: 58-64.
13. Kaplar M, Kappelmayer J, Veszpremi A et al. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419-422.
14. Antoniades C, Bakogiannis C, Tousoulis D et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
15. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
16. Lievens D, Zernecke A, Seijkens T et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
17. Renesto P, Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophilmediated platelet activation. Blood 1993; 82: 139-144.
18. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
19. Stehouwer CD, Nauta JJ, Zeldenrust GC et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323.
20. Collins R, Armitage J, Parish S et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
21. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
22. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
23. Libby P, Okamoto Y, Rocha VZ et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213-220.
24. Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta 2000; 1529: 299-309.
25. Bonetti PO, Lerman LO, Napoli C et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24: 225-248.
26. Goldberg AC, Sapre A, Liu J et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-629.
27. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010; 633: 62-70.
28. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
29. Fioretto P, Mauer M. Histopathology of diabetes nephropathy. Semin Nephrol 2007; 27: 195-207.
30. Ferroni P, Basili S, Falco A et al. Platelet function in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-1291.
31. Sudhop T, Reber M, Tribble D et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009; 50: 2117-2123.
32. Li N, Wallen NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374-1379.
33. Farndale RW, Lisman T, Bihan D et al. Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. Biochem Soc Trans 2008; 36: 241-250.
34. Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154-161.
35. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-2105.
36. Schwabe RF, Engelmann H, Hess S et al. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 1999; 117: 153-158.
37. Lajer M, Tarnow I, Michelson AD et al. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 2010; 21: 525-532.
38. Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
39. Santini E, Madec S, Correti V et al. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest 2008; 31: 660-665.
40. Malmstr RE, Settergren M, Bohm F et al. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb Haemost 2009; 101: 157-164.
41. Broijersen A, Eriksson M, Leijd B et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 273-278.
42. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.